Vertex Pharmaceuticals company information

버텍스 파머슈티컬NASDAQ:VRTX · Nasdaq · Healthcare

$504.73-0.40%

2026-10-02 close

Vertex Pharmaceuticals's company information is shown as of 2026-10-02. It is a security listed on Nasdaq, ticker VRTX. There are 14 published related companies.

About this company

Vertex Pharmaceuticals last closed at $504.73 (-0.40%) on 2026-10-02. Signals today: Death cross, MACD bullish cross. Listed on Nasdaq.

1 guru reporting 13F holdings

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F is quarterly and may be filed up to 45 days later.

Curated gurus reporting this holding

A curated subset of well-known investors — not the full institutional ownership.

Bridgewater Associates10,865주2026-06-30 · 증감 -2492주

Suppliers, competitors and related stocks

AbbVieCompetitor
낭포성섬유증(CF) 및 면역질환 영역에서 경쟁
ModernaCompetitor
mRNA 기반 희귀질환·유전질환 치료제 개발 경쟁
PfizerCompetitor
신약 개발 전반과 일부 희귀질환·진통제 영역에서 경쟁
NovartisCompetitor
희귀질환·유전자치료 및 전문의약품 분야 경쟁
CRISPR TherapeuticsCustomer
Vertex와 공동개발한 유전자편집 치료제 사업의 핵심 파트너
Sangamo TherapeuticsCompetitor
유전자편집·유전질환 치료제 개발에서 경쟁
AstraZenecaCompetitor
호흡기·염증성 질환 및 전문의약품 시장에서 경쟁
Ionis PharmaceuticalsCompetitor
희귀질환·RNA 기반 치료제 분야에서 경쟁
F. Hoffmann-La RocheCompetitor
면역질환·희귀질환 및 정밀의학 분야에서 경쟁
Alnylam PharmaceuticalsCompetitor
RNA 치료제 기반 희귀질환 시장에서 경쟁
ArgenxCompetitor
면역질환 치료제 영역에서 경쟁
Takeda PharmaceuticalCompetitor
희귀질환·면역질환 및 글로벌 전문의약품 시장에서 경쟁
Cystic Fibrosis FoundationRelated theme
Vertex의 핵심 매출원인 CF 치료제 시장과 직결된 질환 생태계
BioMarin PharmaceuticalCompetitor
희귀질환 치료제 개발과 상용화에서 경쟁

Major stocks in the same sector

2026-10-04 dataset

📦 ETFs holding this stock

by weight · top-10 constituents basis

Passive money holding this stock ≈ $1.5B(lower bound — top-10 basis, not a forecast)

Factual holdings info from daily disclosures — not a recommendation.

Look up another stock →

Quantus Signal · live data · not investment advice · Privacy Policy